CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...
Phase 3
Chicago, Illinois, United States and 47 other locations
binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...
Phase 3
Park Ridge, Illinois, United States and 227 other locations
efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...
Phase 3
Chicago, Illinois, United States and 49 other locations
of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma...
Phase 1, Phase 2
Chicago, Illinois, United States and 24 other locations
To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investig...
Phase 2
Chicago, Illinois, United States and 55 other locations
A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibit...
Phase 2
Chicago, Illinois, United States and 11 other locations
to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...
Phase 3
Chicago, Illinois, United States and 171 other locations
treatment (pembrolizumab) in participants with advanced melanoma.The study will involve initial administration of EDP1503 for a run-in perio...
Phase 2
Chicago, Illinois, United States
treatment of adult subjects with completely treated high-risk ocular melanoma, as defined in eligibility criteria, without evidence of metas...
Phase 2
Chicago, Illinois, United States and 5 other locations
and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recur...
Phase 3
Chicago, Illinois, United States and 128 other locations
Clinical trials
Research sites
Resources
Legal